LB-80380 maleate salt

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 598502

CAS#: 1039623-01-2

Description: LB-80380 maleate salt is a novel phosphonate nucleoside for the potential treatment of HBV infection.


Chemical Structure

img
LB-80380 maleate salt
CAS# 1039623-01-2

Theoretical Analysis

MedKoo Cat#: 598502
Name: LB-80380 maleate salt
CAS#: 1039623-01-2
Chemical Formula: C26H38N5O11P
Exact Mass: 0.00
Molecular Weight: 627.580
Elemental Analysis: C, 49.76; H, 6.10; N, 11.16; O, 28.04; P, 4.94

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: LB-80380 maleate salt; LB 80380 maleate salt; LB80380 maleate salt;

IUPAC/Chemical Name: ((((1-((2-amino-9H-purin-9-yl)methyl)cyclopropoxy)methyl)phosphanediyl)bis(oxy))bis(methylene) bis(2,2-dimethylpropanoate) maleate

InChi Key: XVQGVHXBNVFYSR-BTJKTKAUSA-N

InChi Code: InChI=1S/C22H34N5O7P.C4H4O4/c1-20(2,3)17(28)30-12-33-35(34-13-31-18(29)21(4,5)6)14-32-22(7-8-22)10-27-11-25-15-9-24-19(23)26-16(15)27;5-3(6)1-2-4(7)8/h9,11H,7-8,10,12-14H2,1-6H3,(H2,23,24,26);1-2H,(H,5,6)(H,7,8)/b;2-1-

SMILES Code: NC1=NC=C2N=CN(CC3(OCP(OCOC(C(C)(C)C)=O)OCOC(C(C)(C)C)=O)CC3)C2=N1.O=C(O)/C=C\C(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 627.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Papatheodoridis GV, Manolakopoulos S. Drug evaluation: LB-80380--a novel phosphonate nucleoside for the potential treatment of HBV infection. Curr Opin Mol Ther. 2006 Aug;8(4):352-7. Review. PubMed PMID: 16955699.

2: Lampertico P. Oral antiviral therapy for hepatitis B: the case of besifovir, a new kid on the block with a long way to go. Gut. 2014 Jun;63(6):869-70. doi: 10.1136/gutjnl-2013-305859. Epub 2013 Oct 25. PubMed PMID: 24162592.

3: Yuen MF, Ahn SH, Lee KS, Um SH, Cho M, Yoon SK, Lee JW, Park NH, Kweon YO, Sohn JH, Lee J, Kim JA, Lai CL, Han KH. Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study. J Hepatol. 2015 Mar;62(3):526-32. doi: 10.1016/j.jhep.2014.10.026. Epub 2014 Oct 25. PubMed PMID: 25450709.

4: Lai CL, Ahn SH, Lee KS, Um SH, Cho M, Yoon SK, Lee JW, Park NH, Kweon YO, Sohn JH, Lee J, Kim JA, Han KH, Yuen MF. Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut. 2014 Jun;63(6):996-1004. doi: 10.1136/gutjnl-2013-305138. Epub 2013 Aug 26. PubMed PMID: 23979965.

5: Jung JA, Kim SR, Kim TE, Kim JR, Lee SY, Huh W, Ko JW. Pharmacokinetic comparison of the maleate and free base formulations of LB80380, a novel nucleotide analog, in healthy male volunteers. Int J Clin Pharmacol Ther. 2012 Sep;50(9):657-64. PubMed PMID: 22981147.

6: Yuen MF, Han KH, Um SH, Yoon SK, Kim HR, Kim J, Kim CR, Lai CL. Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. Hepatology. 2010 Mar;51(3):767-76. doi: 10.1002/hep.23462. PubMed PMID: 20091678.

7: Fung J, Lai CL, Yuen MF. LB80380: a promising new drug for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2008 Oct;17(10):1581-8. doi: 10.1517/13543784.17.10.1581 . Review. PubMed PMID: 18808318.

8: Choi JR, Cho DG, Roh KY, Hwang JT, Ahn S, Jang HS, Cho WY, Kim KW, Cho YG, Kim J, Kim YZ. A novel class of phosphonate nucleosides. 9-[(1-phosphonomethoxycyclopropyl)methyl]guanine as a potent and selective anti-HBV agent. J Med Chem. 2004 May 20;47(11):2864-9. PubMed PMID: 15139764.

9: Yuen MF, Kim J, Kim CR, Ngai V, Yuen JC, Min C, Kang HM, Shin BS, Yoo SD, Lai CL. A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. Antivir Ther. 2006;11(8):977-83. PubMed PMID: 17302367.

10: Mak LY, Seto WK, Lai CL, Yuen MF. Pharmacokinetic evaluation of besifovir for the treatment of HBV infection. Expert Opin Drug Metab Toxicol. 2018 Jan;14(1):101-106. doi: 10.1080/17425255.2018.1417983. Epub 2017 Dec 18. Review. PubMed PMID: 29237296.